Ipsen Group

Press releases

Ordinary Shareholders’ Meeting of IPSEN S.A. held on 4 June 2014
Posted: June 4, 2014, 5:09 pm
Ipsen announces a step forward in the resupply of Increlex® in the U.S.
Posted: May 13, 2014, 7:00 am
Ipsen’s first quarter 2014 sales
Posted: April 30, 2014, 7:00 am
Ipsen announces a first set of results on positive phase III clinical study of Dysport® in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul
Posted: April 12, 2014, 1:00 pm
The Fondation Ipsen celebrates its 30th anniversary with a prestigious conference on the perspectives of cancer research, “Biology viewed through the prism of cancer”, attended by 8 Nobel Prize laureates and the greatest scientists in biomedical research
Posted: April 11, 2014, 8:00 am
Ipsen eligible for PEA-PME and included in CAC® PME index by Euronext
Posted: April 9, 2014, 8:00 am
Ipsen announces that its controlling shareholder, Mayroy, sold approximately 7% of Ipsen’s share capital via private placement
Posted: March 20, 2014, 7:58 am
Ipsen announces positive results from phase IIa clinical study of Dysport® in the treatment of patients with Neurogenic Detrusor Overactivity (NDO)
Posted: March 18, 2014, 8:25 am
Ipsen’s 2013 results and 2014 financial objectives
Posted: February 28, 2014, 7:55 am
Ipsen announces positive top line results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with prostate cancer
Posted: February 7, 2014, 8:25 am